- EBITDA reached €1,251 million with a 13.8% margin, despite weak demand in the US and Europe.
- Recurring cash flow was €464 million, exceeding the €300 million guidance.
- Capacity expansions completed on schedule in the US (DMDS, 1233zd) and Asia (Rilsan\u00ae Clear).
- 2026 targets slight EBITDA growth with capex managed around €600 million.
Financial Performance
In 2025, the company achieved an EBITDA of €1,251 million, maintaining a 13.8% margin despite weak demand in the US and Europe, while Asia showed more dynamism. The company generated a high recurring cash flow of €464 million, surpassing the €300 million guidance, strengthening its balance sheet.
Market Growth and Projects
The company experienced a 16% year-on-year sales growth in key markets such as batteries, sports, 3D printing, healthcare, and fluorospecialties. It successfully started up three capacity expansions in the US (DMDS, 1233zd) and Asia (Rilsan® Clear), all completed on schedule and within budget.
Sustainability and Future Outlook
Significant progress was made in non-financial performance, with improvements in key sustainability indicators. The company proposed a stable dividend of €3.60 per share. Looking ahead to 2026, the company targets slight EBITDA growth at constant currencies, with a focus on strict cost control and managing capex around €600 million.
